Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

ABSTRACT:

Background and objectives

RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components.

Design, setting, participants, & measurements

Post hoc analysis of two clinical trials, the Irbesartan Diabetic Nephropathy Trial (IDNT) and Reduction of End points in Non-insulin dependent diabetes mell

SUBMITTER: Weldegiorgis M 

PROVIDER: S-EPMC5628725 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature